Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure

Background:There is no robust evidence of pharmacological interventions to improve mortality in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF) (HFpEF). In this subanalysis study of the SUPPORT Trial, we addressed the influence of LVEF on the effects of olmesarta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Journal 2016/09/23, Vol.80(10), pp.2155-2164
Hauptverfasser:	Miura, Masanobu, Sakata, Yasuhiko, Miyata, Satoshi, Shiba, Nobuyuki, Takahashi, Jun, Nochioka, Kotaro, Takada, Tsuyoshi, Saga, Chiharu, Shinozaki, Tsuyoshi, Sugi, Masafumi, Nakagawa, Makoto, Sekiguchi, Nobuyo, Komaru, Tatsuya, Kato, Atsushi, Fukuchi, Mitsumasa, Nozaki, Eiji, Hiramoto, Tetsuya, Inoue, Kanichi, Goto, Toshikazu, Ohe, Masatoshi, Tamaki, Kenji, Ibayashi, Setsuro, Ishide, Nobumasa, Maruyama, Yukio, Tsuji, Ichiro, Shimokawa, Hiroaki, on behalf of the SUPPORT Trial Investigators
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiotensin II receptor blocker Angiotensin II Type 1 Receptor Blockers - administration & dosage Disease-Free Survival Female Follow-Up Studies Heart Failure - complications Heart Failure - drug therapy Heart Failure - mortality Heart Failure - physiopathology Heart failure with preserved ejection fraction Humans Hypertension Hypertension - complications Hypertension - diet therapy Hypertension - mortality Hypertension - physiopathology Imidazoles - administration & dosage Kidney - physiopathology Male Middle Aged Olmesartan Prognosis Prospective Studies Stroke Volume - drug effects Survival Rate Tetrazoles - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background:There is no robust evidence of pharmacological interventions to improve mortality in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF) (HFpEF). In this subanalysis study of the SUPPORT Trial, we addressed the influence of LVEF on the effects of olmesartan in HF.Methods and Results:Among 1,147 patients enrolled in the SUPPORT Trial, we examined 429 patients with reduced LVEF (HFrEF, LVEF
ISSN:	1346-9843 1347-4820
DOI:	10.1253/circj.CJ-16-0577